Phase 2Completed

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Sponsor
AstraZeneca (Industry)
Enrollment
116 enrolled
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin; Placebo
Ages
adults, older adults
Registry
NCT00831779

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity

Primary outcomes

  • Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF])

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered